Maxim Group Maintains Buy Rating on Tenon Medical, Lowers Price Target
Maxim Group analyst Anthony Vendetti has maintained a "Buy" rating on Tenon Medical, Inc. while reducing the price target from $10 to $5.
Filings · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Maxim Group analyst Anthony Vendetti has maintained a "Buy" rating on Tenon Medical, Inc. while reducing the price target from $10 to $5.
Tenon Medical, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $1.4 million and a net loss of $6.6 million.
Tenon Medical, Inc. has scheduled the release of its financial results for the third quarter of 2026.
Tenon Medical has successfully completed the initial alpha cases for its new Quickstep Decorticator, a component of its next-generation SImmetry+ SI Joint Fusion System.
https://patentcenter.uspto.gov/applications/18793176/ifw/docs?application=